Skip to content

Screening for Early Cervical Cancer Detection

A Clinical Audit on Screening Program for Early Cervical Cancer Detection.

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06550583
Enrollment
200
Registered
2024-08-13
Start date
2023-06-01
Completion date
2024-09-30
Last updated
2024-08-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cervical Cancer, Cervix Neoplasm

Brief summary

This study is to audit results and adherence to Cervical Screening program before and after the implementing awareness of the WHO guidelines of screening among the multidisciplinary healthcare workers and patients.

Detailed description

Cervical cancer screening is the asymptomatic detection of pre-cancer and cancer in women at risk, with at least one screening suggested for women aged 30-49 years. According to the World Health Survey (2015), 19% of eligible women in developing countries and 63% of those in developed nations had their cervical cancer screening done using a Pap smear or visual inspection with acetic acid (VIA). According to latest estimates by World Health Organization (WHO), in Egypt, 866 women are diagnosed with cervical cancer every year and 373 die from the disease. Cervical cancer is the 13th most common cancer in women in Egypt and the 10th most common cancer in women aged between 15 to 44 years . Statistics from Egyptian studies provide pre invasive cervical lesion incidence levels of 0.3 % to 0.5 % . The human papillomavirus (HPV) is one of the most significant risk factors for cervical cancer. HPV can be transmitted through sexual contact, including vaginal or oral sex with an infected person. HPV has more than 100 strains, of which HPV16 and HPV18 account for about 70% of invasive cervical cancers

Interventions

DIAGNOSTIC_TESTPap smear /Test

Patients will be placed in the lithotomy position, and a sterile bivalve speculum will be inserted into the vagina. • A sample will be taken from the ectocervix by rotating a wooden Ayre spatula 360°. The sample will be quickly smeared onto a labeled glass slide and fixed with 95% ethyl alcohol in a jar to be sent to the Department of Pathology for cytopathological examination

Sponsors

Assiut University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
FEMALE
Age
20 Years to 60 Years

Inclusion criteria

* Women 20-60 years. * Sexually active. * Fulfilling Cervical Check's eligibility criteria for screening at the time of the audit https://www.cervicalcheck.ie/\_fileupload/File/Eligibility%20Framework.pdf

Exclusion criteria

Patient who had underwent to total hysterectomy. * Pregnant or postpartum or post abortive patients * Patient having any history of treatment for cervical dysplasia. * Immunocompromised patients.

Design outcomes

Primary

MeasureTime frameDescription
Screening clinic in Women & Children HospitalBaselineAll women undergo Pap smear test according to inclusion criteria and will be adherence to screening program protocol

Secondary

MeasureTime frameDescription
Via testbaselineVia test will be done to all patients come to screening clinic and Adherence to screening program protocol

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026